Cargando…

Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despi...

Descripción completa

Detalles Bibliográficos
Autores principales: Baysal, Mehmet, Baş, Volkan, Ümit, Elif, Kırkızlar, Hakkı Onur, Demir, Ahmet Muzaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886267/
https://www.ncbi.nlm.nih.gov/pubmed/34162172
http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183
_version_ 1784660628275724288
author Baysal, Mehmet
Baş, Volkan
Ümit, Elif
Kırkızlar, Hakkı Onur
Demir, Ahmet Muzaffer
author_facet Baysal, Mehmet
Baş, Volkan
Ümit, Elif
Kırkızlar, Hakkı Onur
Demir, Ahmet Muzaffer
author_sort Baysal, Mehmet
collection PubMed
description OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despite being widely used, more markers to predict the response to eltrombopag are still needed. In the present study, we aimed to show the association between ANA positivity and eltrombopag response in ITP patients. MATERIALS AND METHODS: Patients who were diagnosed with ITP in the Trakya University Faculty of Medicine’s Department of Hematology and who underwent eltrombopag treatment due to their resistance to steroids and other treatments were included in our study. ANA measurement was performed by indirect fluorescent antibody method and titers of 1:160 and above were considered positive. ANA measurements were made before starting eltrombopag. RESULTS: Forty-five patients were included in our study, 33 being women and 12 men. The mean age of the patients was 45.73 years. There were 14 patients with ANA positivity and 31 patients were found to be ANA-negative. Response rates were higher in ANA-negative patients compared to ANA-positive patients in the 1(st) and 6(th) months of eltrombopag treatment (p<0.05). CONCLUSION: ANA positivity in ITP may indicate unresponsiveness to eltrombopag treatment, a finding that should be further supported by prospective studies involving more patients.
format Online
Article
Text
id pubmed-8886267
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-88862672022-03-11 Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag? Baysal, Mehmet Baş, Volkan Ümit, Elif Kırkızlar, Hakkı Onur Demir, Ahmet Muzaffer Turk J Haematol Research Article OBJECTIVE: Eltrombopag remains a prominent option in the treatment of steroid-dependent or steroid-refractory immune thrombocytopenia (ITP) patients. Unfortunately, not all patients respond to eltrombopag. Antinuclear antibody (ANA) positivity can be seen at rates of up to 30% in ITP patients. Despite being widely used, more markers to predict the response to eltrombopag are still needed. In the present study, we aimed to show the association between ANA positivity and eltrombopag response in ITP patients. MATERIALS AND METHODS: Patients who were diagnosed with ITP in the Trakya University Faculty of Medicine’s Department of Hematology and who underwent eltrombopag treatment due to their resistance to steroids and other treatments were included in our study. ANA measurement was performed by indirect fluorescent antibody method and titers of 1:160 and above were considered positive. ANA measurements were made before starting eltrombopag. RESULTS: Forty-five patients were included in our study, 33 being women and 12 men. The mean age of the patients was 45.73 years. There were 14 patients with ANA positivity and 31 patients were found to be ANA-negative. Response rates were higher in ANA-negative patients compared to ANA-positive patients in the 1(st) and 6(th) months of eltrombopag treatment (p<0.05). CONCLUSION: ANA positivity in ITP may indicate unresponsiveness to eltrombopag treatment, a finding that should be further supported by prospective studies involving more patients. Galenos Publishing 2022-03 2022-02-23 /pmc/articles/PMC8886267/ /pubmed/34162172 http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183 Text en © Copyright 2022 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Baysal, Mehmet
Baş, Volkan
Ümit, Elif
Kırkızlar, Hakkı Onur
Demir, Ahmet Muzaffer
Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title_full Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title_fullStr Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title_full_unstemmed Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title_short Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
title_sort could antinuclear antibody positivity be a factor affecting treatment response in immune thrombocytopenia patients on eltrombopag?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886267/
https://www.ncbi.nlm.nih.gov/pubmed/34162172
http://dx.doi.org/10.4274/tjh.galenos.2021.2021.0183
work_keys_str_mv AT baysalmehmet couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag
AT basvolkan couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag
AT umitelif couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag
AT kırkızlarhakkıonur couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag
AT demirahmetmuzaffer couldantinuclearantibodypositivitybeafactoraffectingtreatmentresponseinimmunethrombocytopeniapatientsoneltrombopag